Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
WAT
BUYWaters Corporation · Healthcare · United States · $36.8B · Avg Vol: $341M/d
COMPANY DESCRIPTION
Waters Corporation develops and manufactures analytical laboratory instruments, software, and services for liquid chromatography, mass spectrometry, and thermal analysis, serving pharmaceutical, life science, and industrial research. It is a market leader in high-performance liquid chromatography (HPLC) and mass spectrometry, benefiting from a deeply embedded installed base, proprietary technologies, and high customer switching costs. Waters is a critical enabler of scientific research and quality control across diverse industries.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.0B | 3.0B | 3.0B | 3.2B | 2.1% | 3.8B | 6.4B | 7.1B | 49.9% |
| EPS | 11.80 | 10.87 | 10.75 | 10.80 | -2.9% | 7.62 | 11.94 | 13.57 | 12.1% |
| Shares | 59.1M | 59.2M | 59.4M | 59.5M | +0.8% | — | — | — | — |
| Debt | 1.7B | 2.4B | 1.7B | 1.5B | -3.6% | 5.6B | — | — | — |
| Equity | 504.5M | 1.2B | 1.8B | 2.6B | 71.9% | — | — | — | — |
| Op CF | 611.7M | 602.8M | 762.1M | 652.6M | 2.2% | 389.6M | — | — | — |
| Inv CF | -108.0M | -1.4B | -143.1M | -152.3M | — | — | — | — | — |
| Fin CF | -509.6M | 755.0M | -696.7M | -237.2M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of WAT are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| WAT | Waters Corporation(you) | $36.8B | 65 | BUY |
| IQV | IQVIA Holdings Inc. | $34.7B | 67 | BUY |
| IDXX | IDEXX Laboratories, Inc. | $42.9B | 59 | HOLD |
| NTRA | Natera, Inc. | $37.5B | 52 | HOLD |
| A | Agilent Technologies, Inc. | $32.5B | 77 | BUY |
| RVTY | Revvity, Inc. | $12.3B | 65 | BUY |
| ILMN | Illumina, Inc. | $29.4B | 84 | STRONG BUY |
| CRL | Charles River Laboratories International, Inc. | $10.9B | 69 | BUY |
| MEDP | Medpace Holdings, Inc. | $16.8B | 78 | BUY |
| DGX | Quest Diagnostics Incorporated | $25.1B | 89 | STRONG BUY |
Peer medians: ROE -25.6% · P/E 27.6x · Gross margin 50.5%